JP2016513069A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513069A5
JP2016513069A5 JP2015540830A JP2015540830A JP2016513069A5 JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5 JP 2015540830 A JP2015540830 A JP 2015540830A JP 2015540830 A JP2015540830 A JP 2015540830A JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5
Authority
JP
Japan
Prior art keywords
formulation
aqueous
dvd
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513069A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068110 external-priority patent/WO2014071212A2/en
Publication of JP2016513069A publication Critical patent/JP2016513069A/ja
Publication of JP2016513069A5 publication Critical patent/JP2016513069A5/ja
Pending legal-status Critical Current

Links

JP2015540830A 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 Pending JP2016513069A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721364P 2012-11-01 2012-11-01
US61/721,364 2012-11-01
US201361794231P 2013-03-15 2013-03-15
US61/794,231 2013-03-15
PCT/US2013/068110 WO2014071212A2 (en) 2012-11-01 2013-11-01 Stable dual variable domain immunoglobulin protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118152A Division JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Publications (2)

Publication Number Publication Date
JP2016513069A JP2016513069A (ja) 2016-05-12
JP2016513069A5 true JP2016513069A5 (enExample) 2016-12-22

Family

ID=49585619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540830A Pending JP2016513069A (ja) 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Country Status (15)

Country Link
US (3) US20140161817A1 (enExample)
EP (2) EP2914626A2 (enExample)
JP (3) JP2016513069A (enExample)
KR (1) KR20150079866A (enExample)
CN (1) CN105431453A (enExample)
AU (3) AU2013337644A1 (enExample)
BR (1) BR112015009924A2 (enExample)
CA (1) CA2889488A1 (enExample)
HK (1) HK1213204A1 (enExample)
IL (2) IL238264A0 (enExample)
MX (2) MX2015005495A (enExample)
RU (2) RU2020139283A (enExample)
SG (2) SG10201802044RA (enExample)
TW (3) TW201838651A (enExample)
WO (1) WO2014071212A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
US20150291689A1 (en) * 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
PL2946765T3 (pl) * 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
ES2878008T3 (es) * 2015-09-17 2021-11-18 Scripps Research Inst Inmunoconjugados de dominio variable dual y usos de los mismos
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
KR20200036889A (ko) 2017-07-28 2020-04-07 에프. 호프만-라 로슈 아게 이중특이성 항체 제형
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3774925A1 (en) * 2018-04-13 2021-02-17 Institut national de la santé et de la recherche médicale (INSERM) Fc-engineered anti-human ige antibodies and methods of use
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术(上海)有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113082203B (zh) * 2020-01-09 2023-10-20 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd FORMULATION WITH A HMGB1 PARTIAL PEPTIDE
CA3197104A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
US20240101659A1 (en) * 2020-11-25 2024-03-28 Dr. Reddy’S Laboratories Limited Stable therapeutic protein formulation and methods of making the same
US20250333499A1 (en) * 2024-04-30 2025-10-30 Context Therapeutics Inc. Bispecific antibodies and methods of using the same
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
CN120346170B (zh) * 2025-03-13 2026-07-03 武汉友芝友生物制药股份有限公司 抗EpCAM和CD3双特异性抗体药物组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
YU63302A (sh) 2000-02-25 2005-09-19 The Government Of The Un.Stat. Anti-egfrv iii scfvs sa pojačanom citotoksičnošću i povećanim prinosom, imunotoksini na bazi istog i metodi za upotrebu na bazi istog
CA2409361A1 (en) 2000-05-19 2001-11-22 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
PE20020132A1 (es) * 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011117653A1 (en) * 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
TWI500427B (zh) * 2010-05-14 2015-09-21 Abbvie Inc Il-1結合蛋白
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
MX2013007332A (es) * 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.

Similar Documents

Publication Publication Date Title
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2014003370A1 (es) Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
PL3060229T3 (pl) Stabilne, wodne formulacje przeciwciała
AR098168A1 (es) Formulación estable de insulina glulisina
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
TWD168530S (zh) 容器
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
JP2015525307A5 (enExample)
JP2016031825A5 (enExample)
JP2015516943A5 (enExample)
TWD180200S (zh) 殺菌容器之部分
JP2014529579A5 (enExample)
JP2013535391A5 (enExample)
CY1123536T1 (el) Τρυγικο αλας του 5-χλωρο-θειοφαινο-2-καρβοξυλικου οξεος [(s)-2-[meθyλo-3-(2-oξo-πυρρολιδιν-1-υλ)-βενζολοσουλφονυλαμινο]-3-(4-μεθυλο-πιπεραζιν-1-υλ)-3-οξο-προπυλ]αμιδιου
TWD167748S (zh) 電連接器
JP2012186616A5 (enExample)
JP2016107746A5 (enExample)
CN302028187S (zh) 酒瓶(丰谷酒王15年)
CN302314225S (zh) 眼镜(tw14)
CN302314211S (zh) 眼镜(tw21)
CN302314221S (zh) 眼镜(026)
CN302586459S (zh) 燃气灶(7)
CN302586458S (zh) 燃气灶(8)
CN302484115S (zh) 文件夹(kk0447)